An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.
Back to Lifestyle
Lifestyle
September 30, 2026 at 2:15 PM
STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial
STAT News
Excerpt from STAT News.